Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.

Serebruany VL.

Thromb Haemost. 2011 May;105(5):752-9. doi: 10.1160/TH10-12-0807. Epub 2011 Mar 8.

PMID:
21384079
2.

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.

PMID:
22104457
3.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
4.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
5.

Ticagrelor: from discovery to Phase III clinical trial.

Siller-Matula JM, Jilma B.

Future Cardiol. 2010 Nov;6(6):753-64. doi: 10.2217/fca.10.89. Review.

PMID:
21142630
7.

Advances in antiplatelet treatment for acute coronary syndromes.

Eshaghian S, Shah PK, Kaul S.

Heart. 2010 May;96(9):656-61. doi: 10.1136/hrt.2009.185983. Epub 2009 Nov 11. Review.

PMID:
19910292
8.

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

Anderson SD, Shah NK, Yim J, Epstein BJ.

Ann Pharmacother. 2010 Mar;44(3):524-37. doi: 10.1345/aph.1M548. Epub 2010 Feb 2. Review.

PMID:
20124464
9.

[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].

Hinneburg I.

Med Monatsschr Pharm. 2011 Jul;34(7):226-32. Review. German.

PMID:
21809597
10.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
11.

Clinical use of clopidogrel in acute coronary syndrome.

Zambahari R, Kwok OH, Javier S, Mak KH, Piyamitr S, Tri Ho HQ, Hwang JJ, Suryawan R, Chow WH.

Int J Clin Pract. 2007 Mar;61(3):473-81. Review.

13.

Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.

Husted S.

Fundam Clin Pharmacol. 2009 Feb;23(1):1-9. doi: 10.1111/j.1472-8206.2008.00660.x. Review.

PMID:
19267766
14.
15.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
16.

Prasugrel: a critical comparison with clopidogrel.

Reinhart KM, White CM, Baker WL.

Pharmacotherapy. 2009 Dec;29(12):1441-51. doi: 10.1592/phco.29.12.1441. Review.

PMID:
19947804
17.

Risk:benefit assessment of old medicines.

Garattini S, Bertelé V.

Br J Clin Pharmacol. 2004 Dec;58(6):581-6. Review.

Supplemental Content

Support Center